-+ 0.00%
-+ 0.00%
-+ 0.00%

Liminatus Pharma appeals Nasdaq delisting notice after missing $50 million market value rule

PUBT·05/27/2026 20:35:14
Listen to the news
Liminatus Pharma appeals Nasdaq delisting notice after missing $50 million market value rule
  • Liminatus Pharma faces Nasdaq delisting risk for failing to meet $50 million MVLS and $15 million MVPHS continued-listing thresholds.
  • Nasdaq issued a noncompliance notice on May 20, 2026; trading suspension was set for May 29, 2026 absent an appeal by May 27.
  • An appeal request filed May 26, 2026 triggers a stay, pausing any suspension or delisting pending a Nasdaq Hearings Panel decision.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Liminatus Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-066974), on May 27, 2026, and is solely responsible for the information contained therein.